ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew factors predicting response in patients with a PD-L1 tumor proportion score (TPS) ≥ 50% for locally advanced or metastatic non-small cell lung cancer (NSCLC) are needed to better select first-line therapy. Based on the literature, we previously developed a radiomic model predicting the KEAP1/NFE2L2 mutational status.
methodThis was a retrospective monocenter study including 94 consecutive patients with advanced or metastatic PD-L1 ≥ 50% NSCLC, treated with pembrolizumab, who underwent a pre-therapeutic FDG-PET/CT and were followed up for 1 year. Seventy-seven patients who did not progress within the first 60 days of treatment were analyzed. Each primary lesion was segmented by 2 physicians on PET and CT scans. Radiomic features were calculated using MIM software on both PET and CT imaging. A previously developed KEAP1/NFE2L2 radiomic prediction model (called MUT
resultsThe main characteristics of this cohort were: median age of 67.0 years [range, 48.0-84.0], sex ratio M/F = 60/17, 74.0% of patients with a histopathology of adenocarcinoma and 85.0% with a stage IV disease. The median follow-up was 20.0 months [range, 15.3-23.9]. Fifty-six (72.2%) patients experienced a disease progression with a median PFS of 11.8 months (CI95% 8.6-15.8) among which 51 (66.2%) died. In univariable analysis, MUT
conclusionIn PD-L1 TPS ≥ 50% NSCLC patients treated with pembrolizumab, our results suggest an improved PFS in patients predicted to be KEAP1/NFE2L2 mutated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.